Texas

Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.

With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.

Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.

Preclinical data for its drug candidate, LP-184, reportedly showed over 90 percent efficacy in shrinking pancreatic cancer tumors in mouse models in vitro, in-vivo, and ex-vivo.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Every week there are numerous scientific studies published. This week there was an unusual number of research stories revolving around Alzheimer’s disease. Here’s a look at some of the more interesting ones.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

As BioSpace releases its third annual 2021 U.S. Life Sciences Salary Report, there are hopeful surprises and unsettling truths.

Please check out the biopharma industry’s COVID-19 stories that are trending for June 22, 2021.